β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2019

ABSTRACT

Epidermal Growth Factor Receptor tyrosine-kinase inhibitors (EGFR-TKIs), including gefitinib,erlotinib and icotinib demonstrate excellent effect on the treatment of non small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance. Detailed Description Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,erlotinib and icotinib demonstrate excellent effect on the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. Beta-elemene, a natural plant drug extracted from Curcuma wenyujin, has been used as an antitumor drug for different tumors, including NSCLC via mechanism that inhibits Ras/Mapk signaling and cell cycle progression.In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance. main objectives: progression-free survival (PFS) ratio in 12 week the secondary goal: Objective Response Rate (ORR) More... »

URL

https://clinicaltrials.gov/show/NCT03123484

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Epidermal Growth Factor Receptor tyrosine-kinase inhibitors \uff08EGFR-TKIs\uff09, including gefitinib\uff0cerlotinib and icotinib demonstrate excellent effect on the treatment of non small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance.\n\nDetailed Description\nEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib\uff0cerlotinib and icotinib demonstrate excellent effect on the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. Beta-elemene, a natural plant drug extracted from Curcuma wenyujin, has been used as an antitumor drug for different tumors, including NSCLC via mechanism that inhibits Ras/Mapk signaling and cell cycle progression.In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance. main objectives: progression-free survival (PFS) ratio in 12 week the secondary goal: Objective Response Rate \uff08ORR\uff09", 
    "endDate": "2019-10-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03123484", 
    "keywords": [
      "Combine", 
      "non small cell lung cancer", 
      "epidermal growth factor receptor", 
      "tyrosine kinase inhibitor", 
      "patient", 
      "EGFR mutation", 
      "drug", 
      "resistance", 
      "investigator aim", 
      "efficacy", 
      "beta", 
      "EGFR", 
      "advanced non-small cell lung cancer", 
      "epidermal growth factor receptor tyrosine kinase inhibitor", 
      "Non-Small-Cell Lung Carcinoma", 
      "plant", 
      "antitumor drug", 
      "different tumor", 
      "signaling", 
      "cell cycle progression", 
      "main objective", 
      "Disease-Free Survival", 
      "ratio", 
      "secondary goal", 
      "objective response rate"
    ], 
    "name": "\u03b2-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03123484"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00024.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.452828.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412636.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412449.e", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.415460.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.452435.1", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s12032-013-0488-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008638801", 
          "https://doi.org/10.1007/s12032-013-0488-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cllc.2016.08.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009039367"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.2042-7158.2011.01371.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045134756"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4268/cjcmm20130934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072427723"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2017.02.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083917524"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03123484"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03123484'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03123484'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03123484'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03123484'


 

This table displays all metadata directly associated to this object as RDF triples.

68 TRIPLES      16 PREDICATES      49 URIs      34 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03123484 schema:about anzsrc-for:3142
2 schema:description Epidermal Growth Factor Receptor tyrosine-kinase inhibitors (EGFR-TKIs), including gefitinib,erlotinib and icotinib demonstrate excellent effect on the treatment of non small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance. Detailed Description Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib,erlotinib and icotinib demonstrate excellent effect on the treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, patients who are initially sensitive to the drugs eventually become resistance. Beta-elemene, a natural plant drug extracted from Curcuma wenyujin, has been used as an antitumor drug for different tumors, including NSCLC via mechanism that inhibits Ras/Mapk signaling and cell cycle progression.In this study, the investigators aim to explore the efficacy of beta-elemene, combining with EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance. main objectives: progression-free survival (PFS) ratio in 12 week the secondary goal: Objective Response Rate (ORR)
3 schema:endDate 2019-10-01T00:00:00Z
4 schema:keywords Combine
5 Disease-Free Survival
6 EGFR
7 EGFR mutation
8 Non-Small-Cell Lung Carcinoma
9 advanced non-small cell lung cancer
10 antitumor drug
11 beta
12 cell cycle progression
13 different tumor
14 drug
15 efficacy
16 epidermal growth factor receptor
17 epidermal growth factor receptor tyrosine kinase inhibitor
18 investigator aim
19 main objective
20 non small cell lung cancer
21 objective response rate
22 patient
23 plant
24 ratio
25 resistance
26 secondary goal
27 signaling
28 tyrosine kinase inhibitor
29 schema:name β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
30 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03123484
31 schema:sdDatePublished 2019-03-07T15:27
32 schema:sdLicense https://scigraph.springernature.com/explorer/license/
33 schema:sdPublisher Na4f930f5b80b41738d286e319ba03f62
34 schema:sponsor https://www.grid.ac/institutes/grid.412449.e
35 https://www.grid.ac/institutes/grid.412636.4
36 https://www.grid.ac/institutes/grid.415460.2
37 https://www.grid.ac/institutes/grid.452435.1
38 https://www.grid.ac/institutes/grid.452828.1
39 schema:startDate 2017-04-01T00:00:00Z
40 schema:subjectOf sg:pub.10.1007/s12032-013-0488-9
41 https://doi.org/10.1016/j.cllc.2016.08.004
42 https://doi.org/10.1016/j.critrevonc.2017.02.009
43 https://doi.org/10.1111/j.2042-7158.2011.01371.x
44 https://doi.org/10.4268/cjcmm20130934
45 schema:url https://clinicaltrials.gov/show/NCT03123484
46 sgo:license sg:explorer/license/
47 sgo:sdDataset clinical_trials
48 rdf:type schema:MedicalStudy
49 Na4f930f5b80b41738d286e319ba03f62 schema:name Springer Nature - SN SciGraph project
50 rdf:type schema:Organization
51 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
52 rdf:type schema:DefinedTerm
53 sg:pub.10.1007/s12032-013-0488-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008638801
54 https://doi.org/10.1007/s12032-013-0488-9
55 rdf:type schema:CreativeWork
56 https://doi.org/10.1016/j.cllc.2016.08.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009039367
57 rdf:type schema:CreativeWork
58 https://doi.org/10.1016/j.critrevonc.2017.02.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083917524
59 rdf:type schema:CreativeWork
60 https://doi.org/10.1111/j.2042-7158.2011.01371.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1045134756
61 rdf:type schema:CreativeWork
62 https://doi.org/10.4268/cjcmm20130934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072427723
63 rdf:type schema:CreativeWork
64 https://www.grid.ac/institutes/grid.412449.e schema:Organization
65 https://www.grid.ac/institutes/grid.412636.4 schema:Organization
66 https://www.grid.ac/institutes/grid.415460.2 schema:Organization
67 https://www.grid.ac/institutes/grid.452435.1 schema:Organization
68 https://www.grid.ac/institutes/grid.452828.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...